The additive effects on intraocular pressure of combining nipradilol 0.25% and latanoprost 0.005% ophthalmic solutions: a prospective, randomized, multicenter study.
OBJECTIVE
To investigate the effectiveness of combining nipradilol 0.25% and latanoprost 0.005% ophthalmic solutions in improving the intraocular pressures (IOPs) in glaucoma patients.


METHODS
We divided the 53 patients into two groups, those who had been treated with latanoprost and those who had been treated with nipradilol. We administered to the first group one dose of latanoprost daily for 12 weeks and to the second group one dose of nipradilol daily for 12 weeks. Each group then received both solutions for another 12 weeks; the latanoprost group received nipradilol and the nipradilol group received latanoprost. IOPs were measured at each 4-week visit.


RESULTS
In the patients previously treated with latanoprost, the mean IOP was 19.6+/-2.5 mmHg at baseline, and 14.9+/-2.4 mmHg (23.7% reduction) after 12 weeks of latanoprost monotherapy. The addition of nipradilol decreased the IOP to 13.8+/-1.9 mmHg (29.0% reduction). In the group previously treated with nipradilol, the mean IOP was 20.2+/-3.1 mmHg at baseline, and 16.7+/-3.5 mmHg (17.1% reduction) after 12 weeks of nipradilol monotherapy. Addition of latanoprost decreased the IOP to 14.2+/-3.2 mmHg (29.5% reduction).


CONCLUSIONS
Latanoprost and nipradilol are more effective as a combination therapy than each one by itself.
Tsuru
Tadahiko
T
Department of Ophthalmology, Jichi Medical University School of Medicine, Tochigi, Japan. ttsuru@jichi.ac.jp.|Tadahiko Tsuru, Department of Ophthalmology, Jichi Medical University School of Medicine, 3311-1 Yakushiji, Shimotsuke, Tochigi, 329-0498, Japan. ttsuru@jichi.ac.jp.
Kitazawa
Yoshiaki
Y
Akasaka Kitazawa Eye Clinic, Tokyo, Japan.
Usui
Masahiko
M
3 Department of Ophthalmology, Tokyo Medical University, Tokyo, Japan.
Ueno
Satoki
S
Department of Ophthalmology, St. Marianna University School of Medicine, Kanagawa, Japan.
Azuma
Ikuo
I
Osaka Medical College, Osaka, Japan.
Masuda
Kanjiro
K
Japanese Red Cross Medical Center, Tokyo, Japan.
D000959:Antihypertensive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D005902:Glaucoma, Open-Angle / Q000188:drug therapy*; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects*; D000077338:Latanoprost; D008297:Male; D008875:Middle Aged; D009883:Ophthalmic Solutions / Q000009:adverse effects / Q000627:therapeutic use; D011412:Propanolamines / Q000009:adverse effects / Q000627:therapeutic use*; D011446:Prospective Studies; D011461:Prostaglandins F, Synthetic / Q000009:adverse effects / Q000627:therapeutic use*; D014065:Tonometry, Ocular; D016896:Treatment Outcome; D014794:Visual Fields / Q000187:drug effects
D000959:Antihypertensive Agents; D009883:Ophthalmic Solutions; D011412:Propanolamines; D011461:Prostaglandins F, Synthetic; D000077338:Latanoprost; C036089:nipradilol